Navigation Links
National Brain Tumor Society Responds to Results of Avastin Clinical Trials
Date:6/3/2013

Boston, MA (PRWEB) June 03, 2013

National Brain Tumor Society, the largest nonprofit in the United States dedicated to the brain tumor community, issues the following statement regarding clinical trial results involving the cancer drug Avastin reported at the American Society of Clinical Oncology’s 2013 Annual Meeting:

"Beginning in May of 2009, drug maker Genentech received accelerated approval from the U.S. Food and Drug Administration (FDA) to market Avastin (bevacizumab) for the treatment of recurrent glioblastoma multiforme (GBM). National Brain Tumor Society has since followed the progress of Genentech’s required post-market study of Avastin called AVAglio, and has also sought input from the brain tumor community about the role Avastin has played as one of only four approved brain cancer drugs.

National Brain Tumor Society is deeply disappointed in the recently announced results of the AVAglio clinical trial. This trial revealed that Avastin (in combination with standard of care treatments) did not significantly prolong the lives of newly diagnosed GBM patients.

We are equally concerned with additional findings from a large, National Cancer Institute (NCI)-supported clinical trial conducted by the Radiation Therapy Oncology Group (RTOG). Similar to the AVAglio trial, the RTOG study did not show statistically significant increases in overall survival for newly diagnosed GBM patients taking Avastin in combination with standard of care treatments. Data from the AVAglio and RTOG studies collectively have provided mixed results on issues such as progression-free survival (i.e. a measure of tumor growth in response to a therapy) and quality of life, which will require careful and further analysis to better understand their full meaning in terms of patient care.

Avastin is an important part of the current limited treatment landscape for many brain cancer patients. National Brain Tumor Society understands that Avastin has helped some brain cancer patients have a higher quality of life in their last months, and as such we think it is important that it remains an available treatment option for patients and doctors.

While we had hoped to see positive overall survival figures, the gold standard of measurement for oncology drugs, further analysis of the recently concluded trials, as well as an anticipated FDA reaction, will necessitate larger discussions about Avastin’s role as a brain cancer treatment. Most important for patients, Avastin is still approved as a treatment for recurrent GBM.

The discouraging results from the AVAglio and RTOG studies underscore the critical importance of advancing research for the discovery of new, more durable therapies, while advocating for the continued availability of all treatment options for brain tumor patients.

Going forward, the National Brain Tumor Society will work with our medical and scientific advisors to bring clarity to the issue of how Avastin and other targeted therapies fit into the current brain tumor treatment standard. Additionally, we are steadfastly determined to support the development of new therapeutic approaches through our integrated research and public policy programs.

Brain cancer is one of the most deadly and complex forms of all cancers. There are no known causes, no prevention methods, and few treatment options. National Brain Tumor Society is fiercely committed to continuing the fight to find effective, durable treatments and one day a cure."

About National Brain Tumor Society
National Brain Tumor Society is the largest nonprofit organization dedicated to the brain tumor community in the United States. We are fiercely committed to finding better treatments, and ultimately a cure, for people living with a brain tumor today and those who will be diagnosed tomorrow. This means aggressively driving strategic research and advocating for public policies, which meet the critical needs of this community. To learn more visit http://www.braintumor.org.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10796128.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. UV Flu Technologies Expands Its International Footprint
2. Elsevier Supports International Crisis Aid Through Pillars of Hope Campaign
3. International Attendance for Networking and Education at Informex Beyond Manufacturing
4. Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses
5. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
6. Experts Launch the Alliance for Fertility Preservation at the International Society for Fertility Preservations 2nd World Congress
7. First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles
8. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
9. PAREXEL International to Present at J.P. Morgan Healthcare Conference
10. DFH Pharma to Collaborate With National Cancer Institute to Develop Second-Generation HIV Maturation Inhibitor Drugs
11. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... Weeks after hosting a carpal tunnel syndrome ... Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, has announced the addition ... is a state-of-the-art technology and only 1 of about 3 currently available in the ...
(Date:5/27/2016)... Jersey and READING, ... -- Indegene ( http://www.indegene.com ), ... marketingorientierten Lösungen für die Life-Science-Branche, Pharmaunternehmen und ... bekannter weltweiter Anbieter von innovativen wissenschaftlichen Support-Services ... des Starts von IntraScience heute den Ausbau ...
(Date:5/26/2016)... ISELIN, New Jersey and ... -- Indegene ( http://www.indegene.com ), a ... solutions to life science, pharmaceutical and healthcare organisations ... provider of innovative scientific support throughout the product ... alliance with the launch of IntraScience. ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising treatments in ... the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient ... this year following FDA approval of a second application for a single patient, ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)...   Unisys Corporation (NYSE: UIS ) today ... is testing its biometric identity solution at the Otay Mesa ... help identify certain non-U.S. citizens leaving the country. ... help determine the efficiency and accuracy of using biometric technologies ... run until May 2016. --> the United ...
Breaking Biology News(10 mins):